Manulife Singapore and Guardant Health unveil joint initiative aimed at improving access to the Guardant360^® liquid biopsy test for Manulife customers with advanced solid tumour cancers

• Manulife Singapore continues its focus on customer health by collaborating with Guardant Health, closing the access gap for the Guardant360 liquid biopsy test.
• With a simple blood draw, the Guardant360 test helps to guide treatment decisions for Manulife customers with advanced solid tumour cancers in this collaboration by providing comprehensive genomic profiling results in seven days upon sample receipt in the laboratory. This test is especially useful for customers who do not have sufficient tumour tissue for comprehensive testing.

10 Dec 2024 – Manulife Singapore today announced a joint initiative with Guardant Health, a leading precision oncology company, to offer eligible customers improved access to the Guardant360^® liquid biopsy test. This collaboration marks a significant milestone in transforming cancer care in Singapore as it enables access for more Manulife customers with advanced solid tumour cancers to be matched with personalised treatments guided by liquid biopsy, which may help improve clinical outcomes.

The strategic collaboration offers Manulife customers greater access to comprehensive genomic profiling across all solid cancers, with specific eligibility criteria and further details to be announced at a later date.

"The collaboration with Guardant Health allows our financial consultants to provide more personalised advice, helping customers make more timely and informed decisions regarding their insurance options during critical moments." said Dr Khoo Kah Siang, CEO of Manulife Singapore. "This is how we continue to raise the standard of care and protection for our customers."

The Guardant360 test covers all guideline-recommended biomarkers across all advanced solid tumours. It provides oncologists with critical genomic and epigenomic insights from a simple blood draw and enables quick and appropriate treatment selection, in seven days upon sample receipt in the laboratory. In addition, the Guardant360 liquid biopsy test fills the testing gap for patients who do not have sufficient tumour tissue for standard tissue biopsies.

Commitment to Customer Health and Innovation

"We are committed to offering solutions that not only protect our customers financially but also help them navigate their health journeys," said Harshal Shah, Chief Marketing Officer, Asia, at Manulife. This collaboration reflects our mission of helping our customers make easier decisions and live better lives, even during the most challenging health conditions."

Liquid biopsies offer patients a more comfortable experience than tissue biopsies, as they are more convenient and less invasive, and they enable oncologists to identify targeted treatment strategies that are suitable for patients with advanced solid tumour cancers.

"We are excited to partner with Manulife and provide improved access to our liquid biopsy technology in Singapore,” said Simran Singh, CEO at Guardant Health AMEA. "For a patient with an advanced solid tumour cancer, time to appropriate treatment is key. Our commitment remains to improve patient outcomes by helping oncologists match patients to the right targeted treatment quickly," he added.

This collaboration with Guardant Health demonstrates Manulife’s dedication to integrating advanced healthcare solutions with its life and health insurance products, creating a holistic offering that empowers customers to take proactive steps in managing their health.

About Manulife Singapore

Serving Singapore since 1899, Manulife Singapore grew from strength to strength to become a leading life insurer that provides a broad range of insurance, retirement and wealth management solutions to meet the financial needs of our customers across their various life stages. Manulife Singapore’s insurance, retirement and wealth management solutions are distributed through our own affiliated financial adviser representatives and our specialist partners, including banks and other financial advisory firms. For more information on Manulife Singapore, please visit manulife.com.sg.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealthamea.com and follow the company on LinkedIn , X (Twitter) and Facebook.

Media contact

Belinda Wong

Belinda_SJ_Wong@manulife.com

Zaim Zahari / Verona Koh

Manulife@aka-asia.com